Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® HIV / AIDS specialty page provides HIV/AIDS-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

HIV / AIDS NEWS - Page 12

Top 5 Infectious Disease News of the Week—March 25, 2018
In case you missed them, we've compiled the top 5 articles from this past week.
Symfi Triple Combo Once-Daily HIV Treatment Receives FDA Approval
This comes on the heels of 2 recent FDA approvals of 2 Mylan antiretrovirals: Cimduo and Symfi Lo.
Daily TB Therapy Superior to Thrice-Weekly in Patients with HIV
A recent study finds that daily antituberculosis therapy is more effective than a thrice-weekly regimen among HIV-positive patients with pulmonary tuberculosis.
Shorter Duration Tuberculosis Prevention Option Available for People Living With HIV
A new study finds that a 1-month course of antibiotics is as safe & effective as the commonly recommended 9-month course in preventing tuberculosis in those with HIV.
Dolutegravir with Darunavir/Cobicistat Safe to Prescribe in Treatment of HIV, Study Suggests
A new study suggests that an antiretroviral combination of dolutegravir with darunavir/cobicistat can be prescribed safely in the treatment of HIV-1.
Controversial AIDS Expert Robert Redfield Named New CDC Director
AIDS researcher Robert Redfield, MD, has officially been named the new director of the CDC.
Improving Access to Patient Care & Time to Viral Suppression Using HIV Rapid Entry Programs
Implementation of a rapid entry program decreased time to first provider appointment, time to initiation of ART, and time to viral suppression in the Southern United States.
D/C/F/TAF Achieves High Virologic Response Rates Consistent Across Age, Gender, & Race Subgroups in ART-Naive HIV Patients
D/C/F/TAF achieved high virologic response rates that were overall noninferior to the control D/C+F/TDF, as well as favorable bone and renal outcomes that were consistent across age, gender, and race subgroups in phase 3 AMBER trial.
Big advances in treatment can